Methods of using antibodies to block human thymic stromal lymphopoietin (TSLP) receptor activity
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 16, 2014
Issued Date -
N/A
app pub date -
Nov 30, 2012
filing date -
Jun 28, 2000
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TSLPR polypeptides.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully